Skip to main content

Table 2 Patients’ demographic and medical characteristics by treatment arm

From: A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment

  Single agent (n = 86) Guideline Therapy (n = 95)
Characteristic No. % Mean SD No. % Mean SD
Age (years)    69.3 14.3    68.1 13.0
Male gender 23 27.4    34 35.8   
Place of care       
 Inpatient palliative care 29 34.5   36 37.9  
 Hospital general ward 28 33.3   37 38.9  
 Private home 27 32.1   22 23.2  
Primary Cancer Diagnosis       
 Breast 8 9.3    15 15.8   
 Lung 9 10.5    12 12.6   
 Colorectal 12 14.0    9 9.5   
 Gynaecologic 14 16.3    12 12.6   
 Gastrointestinal 4 4.7    6 6.3   
 Pancreas 6 7.0    5 5.3   
 Prostate 5 5.8    11 11.6   
 Other 23 26.7    19 20.0   
 Unknown 5 5.8    6 6.3   
Performance statusa (0–100)       
 Median (Interquartile range) 60 (50–70)    60 (50–70)   
Quality of lifeb (1–7)   3.0 1.3   3.0 1.3
Symptom burdenc (0–90)    37.3 16.1    39.0 13.7
Charlson Comorbidity Index    6.1 2.4    6.6 2.1
Vomited in last 24 h 28     30 31.6   
(Yes)   32.6       
Number of vomiting episodes 0     0 (0–10)   
 Median (range)   (0–5)       
Duration of current nausea 13     20 21.1   
 <  1 week 18     26 27.4   
 1 up to 2 weeks 18 15.5    21 22.1   
 2 up to 4 weeks 15 21.4    13 13.7   
 1 up to 2 months 20 21.4    15 15.8   
 ≥ 2 months   17.9       
23.8
Nausea score (0–10)         
 Worst    7.6 1.8    7.4 1.9
 Best    2.1 1.8    1.8 2.0
 Average    5.2 1.4    5.0 1.5
 Distress    4.9 3.0    5.2 3.2
Nausea Interferenced (0–100)    43.6 27.3    43.8 26.0
Nausea - multi-factorial 68 79.1    67 70.5   
 Dominant cause         
 Undetermined 46 53.5    38 40.0   
 Central/CTZe stimulation 16 18.6    27 28.4   
 Gastric stasis 8 9.3    12 12.6   
 Other 16 18.6    18 18.9   
Adverse eventf         
 Fatigue 63 73.3    74 77.9   
 Anticholinergic effects 48 55.8    63 66.3   
 Gastrointestinal upset 51 59.3    57 60.0   
 Anorexia 50 58.1    57 60.0   
 Drowsiness 42 48.8    53 55.8   
 Dizziness 17 19.8    17 17.9   
 Hyper/hypotension 12 14.0    14 14.7   
 Restlessness 4 4.7    5 5.3   
 Extrapyramidal reactions 1 1.0    1 1.0   
 Incoordination 0 0.0    4 4.2   
  1. aAustralian-modified Karnofsky performance status scale
  2. bEORTC-QLQ-C15-PAL
  3. cEdmonton Symptom Assessment Scale
  4. dNausea Interference Scale
  5. eChemo Receptor Trigger Zone
  6. fAny grade